{{Drugbox
| verifiedrevid = 464200749
| IUPAC_name = 1-methyl-3-phenyl-pyrrolidine-2,5-dione
| image = Phensuximide.svg
| width = 140

<!--Clinical data-->
| tradename =
| MedlinePlus = a682237
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 21%
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7612
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 86-34-0
| ATC_prefix = N03
| ATC_suffix = AD02
| ATC_supplemental =
| PubChem = 6839
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00832
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 6578
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6WVL9C355G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00508
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 797

<!--Chemical data-->
| C=11 | H=11 | N=1 | O=2
| molecular_weight = 189.211 g/mol
| smiles = O=C2N(C(=O)CC2c1ccccc1)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = WLWFNJKHKGIJNW-UHFFFAOYSA-N
}}

'''Phensuximide''' is an [[anticonvulsant]] in the [[succinimide]] class.

==External links==
* {{DiseasesDB|31648}}
* {{cite journal |vauthors=Rankin G, Cressey-Veneziano K, Wang R, Brown P | title = Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. | journal = J Appl Toxicol | volume = 6 | issue = 5 | pages = 349â€“56 | year = 1986 | pmid = 3772011 | doi = 10.1002/jat.2550060509}}

{{Anticonvulsants}}

[[Category:Succinimides]]

{{anticonvulsant-stub}}